Last reviewed · How we verify

Peg-IFN + RBV — Competitive Intelligence Brief

Peg-IFN + RBV (Peg-IFN + RBV) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Peg-IFN + RBV (Peg-IFN + RBV) — National Taiwan University Hospital. Pegylated interferon alpha and ribavirin work together to inhibit viral replication and enhance immune response against hepatitis C virus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Peg-IFN + RBV TARGET Peg-IFN + RBV National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin C: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Pegasys /RBV Pegasys /RBV Beijing Kawin Technology Share-Holding Co., Ltd. phase 3 Interferon alfa-2a (pegylated) + nucleoside analog combination Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-interferon alpha 2a and ribavin Peg-interferon alpha 2a and ribavin Hospices Civils de Lyon phase 3 Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Ribavirin, Peg interferon alfa 2b Ribavirin, Peg interferon alfa 2b Brooke Army Medical Center marketed Antiviral combination therapy HCV RNA-dependent RNA polymerase; interferon-alpha receptor
Pegintron + Riba Pegintron + Riba Chang Gung Memorial Hospital marketed Antiviral combination therapy (interferon + nucleoside analog) Interferon-alpha receptor (IFNAR); HCV RNA-dependent RNA polymerase
Peg-IFN + LD RBV for 16 weeks Peg-IFN + LD RBV for 16 weeks National Taiwan University Hospital marketed Antiviral combination therapy Interferon alpha receptor; HCV RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

  1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
  2. National Taiwan University Hospital · 6 drugs in this class
  3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
  4. Hepatitis Resource Network · 1 drug in this class
  5. Hospices Civils de Lyon · 1 drug in this class
  6. MTI Medical Private Limited, Pakistan · 1 drug in this class
  7. Pacific Health Foundation · 1 drug in this class
  8. RedHill Biopharma Limited · 1 drug in this class
  9. Sherief Abd-Elsalam · 1 drug in this class
  10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peg-IFN + RBV — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-ifn-rbv. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: